Wnt signaling dynamics in head and neck squamous cell cancer tumor‐stroma interactions
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Wnt pathway activation maintains the cancer stem cell (CSC) phenotype and promotes tumor progression, making it an attractive target for anti‐cancer therapy. Wnt signaling at the tumor and tumor microenvironment (TME) front have not been investigated in depth in head and neck squamous cell carcinoma (HNSCC). In a cohort of 48 HNSCCs, increased Wnt signaling, including Wnt genes (AXIN2, LGR6, WISP1) and stem cell factors (RET, SOX5, KIT), were associated with a more advanced clinical stage. Key Wnt pathway proteins were most abundant at the cancer epithelial‐stromal boundary. To investigate these observations, we generated three pairs of cancer‐cancer associated fibroblast (CAF) cell lines derived from the same HNSCC patients. 3D co‐culture of cancer spheres and CAFs mimicked these in vivo interactions, and using these we observed increased expression of Wnt genes (eg, WNT3A, WNT7A, WNT16) in both compartments. Of these Wnt ligands, we found Wnt3a, and less consistently Wnt16, activated Wnt signaling in both cancer cells and CAFs. Wnt activation increased CSC characteristics like sphere formation and invasiveness, which was further regulated by the presence of CAFs. Time lapse microscopy also revealed preferential Wnt activation of cancer cells. Wnt inhibitors, OMP‐18R5 and OMP‐54F28, significantly reduced growth of HNSCC patient‐derived xenografts and suppressed Wnt activation at the tumor epithelial‐stromal boundary. Taken together, our findings suggest that Wnt signaling is initiated in cancer cells which then activate CAFs, and in turn perpetuate a paracrine signaling loop. This suggests that targeting Wnt signaling in the TME is essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804
Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction
Glinka, A., Wu, W., Delius, H., Monaghan, A. P., Blumenstock, C., & Niehrs, C. (1998) · Nature · doi:10.1038/34848 · Cited by 1,608
YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response
Azzolin, L., Panciera, T., Soligo, S., Enzo, E., Bicciato, S., Dupont, S., Bresolin, S., Frasson, C., Basso, G., Guzzardo, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.013 · Cited by 1,094
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 1×
“OMP-54F28 is an immunoglobulin G1 (IgG1) region fused with a Fzd receptor that binds and sequestersWnt ligands,(34,35) while OMP-18R5 is a monoclonal antibody that binds to multiple Fzds, including Fzd1, Fzd2, Fzd5, and Fzd8, thus blocking ligand binding.(29)”
BackgroundR-Spondin2 Is a Secreted Activator of Wnt/β-Catenin Signaling and Is Required for Xenopus Myogenesis
Kazanskaya, O., Glinka, A., del Barco Barrantes, I., Stannek, P., Niehrs, C., & Wu, W. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.07.019 · Cited by 431
Rothbächer, U., Laurent, M. N., Deardorff, M. A., Klein, P. S., Cho, K. W. Y., & Fraser, S. E. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.1010 · Cited by 299 · cited 1×
“However, when Wnt ligand binds the Frizzled (Fzd) receptor and LRP5/6 co-receptor,(11,12) the destruction complex is inactivated through Axin degradation.(13,14) Lack of negative regulation allows unphosphorylated β-catenin to accumulate in the cytoplasm and translocate into the nucleus, where it interacts with TCF-LE…”
Background
Cited by
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
Self-citationWnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“Aberrant Wnt/β-catenin signaling has been uncovered to be tightly woven with many aspects of cancers, including the onset, progression, malignant transformation, and so on.(2,3) Evidence-based medicine has further proved that the abnormal activation of this signaling showed nonnegligible effects on cancer-associated m…”
BackgroundAnti-Inflammatory Drugs as Anticancer Agents
Zappavigna, S., Cossu, A. M., Grimaldi, A., Bocchetti, M., Ferraro, G. A., Nicoletti, G. F., Filosa, R., & Caraglia, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072605 · Cited by 395
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
“Ipafricept combined with chemotherapy showed reasonable tolerance in early-phase clinical trials, and remains a therapeutic target of interest.(363,364,366) ETC1922159 is now under assessment in an ongoing clinical trial to test its efficacy as a pembrolizumab combination (Table 2).”
Background
Metadata
- Authors
- Le, P. N., Keysar, S. B., Miller, B., Eagles, J. R., Chimed, T., Reisinger, J., Gomez, K. E., Nieto, C., Jackson, B. C., Somerset, H. L., Morton, J. J., Wang, X., & Jimeno, A.
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 2018-11-28
- Volume
- 58
- Issue
- 3
- Pages
- 398-410
- ISSN
- 0899-1987 (ISSN-L)
- 1098-2744
- OpenAlex
- W2899192636
- Cited by
- 70
- References
- 8
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.